SCHEMBL26089702

SCHEMBL26089702

c1ccc2c(c1)NCCN2c1ccncc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.49
MKNK2 Q9HBH9 1/20 0.49
PIM1 P11309 1/20 0.48
ADRB2 P07550 1/20 0.42
NCF1 P14598 1/20 0.42
PLD1 Q13393 1/20 0.42
BRD4 O60885 1/20 0.39
CHKA P35790 1/20 0.37
PTPN11 Q06124 1/20 0.37
EED O75530 1/20 0.37
AVPR1A P37288 1/20 0.36
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 1/20 0.35
SCN9A Q15858 2/20 0.34
SCN5A Q14524 1/20 0.34
MAPT P10636 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
BRPF1 P55201 1/20 0.34
CYP17A1 P05093 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30910109 1.00 MKNK1 (0.49) MKNK1MKNK2PIM1ADRB2NCF1
SCHEMBL30910136 0.87 PIM1 (0.48) MKNK1MKNK2PIM1BRD4PTPN11
SCHEMBL2330241 0.87 PIM1 (0.48) MKNK1MKNK2PIM1BRD4PTPN11
SCHEMBL30910137 0.87 PIM1 (0.48) MKNK1MKNK2PIM1BRD4PTPN11
SCHEMBL30910118 0.83 PIM1 (0.45) MKNK1MKNK2PIM1BRD4AVPR1A
SCHEMBL26089333 0.83 PIM1 (0.45) MKNK1MKNK2PIM1BRD4AVPR1A
SCHEMBL20112719 0.82 CHRNB2 (0.46) MKNK1MKNK2PIM1SCN9AMAPT
SCHEMBL30910115 0.82 CHRNB2 (0.46) MKNK1MKNK2PIM1SCN9AMAPT
SCHEMBL30910098 0.81 PIM1 (0.44) MKNK1MKNK2PIM1BRD4AVPR1A
SCHEMBL26933806 0.81 PIM1 (0.44) MKNK1MKNK2PIM1BRD4PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4700021-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT Sapiensbio Inc. (KR) 2026-02-25 EP disclosed
WO-2025127848-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT 주식회사 사피엔스바이오 2025-06-19 WO disclosed
EP-4538270-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT Sapiensbio Inc. (KR) 2025-04-16 EP disclosed
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 US disclosed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 EP disclosed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 CN disclosed
WO-2023239227-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT 주식회사 사피엔스바이오 2023-12-14 WO disclosed
WO-2023068755-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 사피엔스바이오 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME RHOA, ACTR2, MFAP1 MKNK1 1034/4885MKNK2 677/4885PIM1 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.